Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...
Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...
Erste Group analysts upgraded Eli Lilly stock from Hold to Buy, citing a robust product demand and a promising pipeline of potential successes. The analysts highlighted the pharmaceutical company's ...
Bank of America updated their “Growth 10” stocks, which are the 10 highest ranking growth stocks according to their ...
The global market for frontotemporal disorders treatment, valued at USD 343.8 million in 2022, is projected to experience steady year-on-year growth, with an anticipated Compound Annual Growth Rate ...
Boston-area filmer Jason Jenkins put together this video on Beantown’s well-known spot you've seen over the years in numerous ...
The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.